Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short versus prolonged infusion of ampicillin-sulbactam in ICU patients with sepsis
IRCT20190425043368N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ampicillin + sulbactam in sepsis (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Clinical cure. Started May 2019; status: completed.
02
Drugs
ampicillin + sulbactam
03
Conditions
sepsis
Beyond the preview
Go deeper on IRCT20190425043368N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190425043368N1.